Chainpharm Limited
Adderss:No.688,Qiushi Rd,Jinshan District,Shanghai.China(Shanghai Fine Chemical Industry Park)
Postcode:201512
Tel:86-21-61727342 13611721451
Fax:86-21-33275302 QQ：1143536688 Skype：chainpharm
Email:info@chainpharm.com
sales@chainpharm.com
China's bio pharmaceutical industry has great potential for development, with a compound annual growth rate of 16%.
According to the industry's 2007 Pharmaceutical Market Report, the global prescription drug market will grow steadily at a compound growth rate of 6.5% over the next five years, reaching $106 trillion by 2022. Biological products will grow steadily, accounting for 30% of the pharmaceutical market in 2022, reaching $326 billion. At present, China's bio pharmaceutical industry is showing explosive growth, annual compound growth rate of 16%. The industry is expected to continue to grow in the future, with huge development potential, mainly affected by policy, technological innovation and capital.
Favorable policies continue
In recent years, China's biopharmaceutical industry has been making good policies. On January 12, 2017, the National Development and Reform Commission officially issued the "13th Five-Year Plan" for the development of biological industry, proposing that by 2020, the scale of the biological industry will reach 8-10 trillion yuan; on May 10, this year, the Ministry of Science and Technology formulated and issued the "13th Five-Year Plan" for Biotechnology innovation, clearly defined the "13th Five-Year Plan" for Biotechnology innovation, plus We will promote the innovation and development of biomedicine in China.
In addition, "Health China 2030" and "Several Policies to Promote the Accelerated Development of Bio-pharmaceutical Industry" and other relevant incentive policies have created a good environment for Bio-pharmaceutical innovation in China, and provided a favorable platform for Bio-pharmaceutical enterprises to develop.
Technological innovation leading
In recent years, with the gradual improvement of biotechnology industry platform and supporting industrial facilities, and the increasing support of relevant policies, the R&D strength of China's bio-pharmaceutical industry enterprises is also increasing, and a number of technologies have emerged on the world stage. For example, in the field of stem cell research, China has also leaped to the forefront of the world, and individual directions in the "leading" position.
In addition, as the domestic biomedical industry situation is improving, the demand for talents is also expanding. According to industry data, there are more than one million people in biomedical R&D in China, 30% of whom have returned from overseas in recent years. The accumulation of these talents will promote further innovation and upgrading of China's biomedicine industry.
Capital inflow into the market
According to authoritative data, China's biomedical market in 2017 is about 145.8 billion yuan, which has become an important driving force for the growth of the global pharmaceutical market. Against this background, huge market potential will inevitably lead to the pursuit of capital.
In addition, with the acceleration of large-scale business restructuring in the pharmaceutical industry, as well as the pull of business integration needs, it is bound to bring more impetus to the future of M&A activities of biomedical enterprises.
The industry said that through diversified capital operations such as investment, mergers and acquisitions, asset restructuring, will further enhance the concentration of the pharmaceutical industry and commerce, promote the development of innovative drugs, high-end medical devices, Internet medical and other emerging areas, and promote the optimization and upgrading of industrial structure.
Generally speaking, with the increasing incentives for independent innovation, China's bio-pharmaceutical industry has basically synchronized with the world's leading regions in some high-end areas, such as PD-1, CAR-T, IDO inhibitors, iRNA and other fields. In addition, with the development of big data and big health, China's bio-pharmaceutical industry has begun to move forward from the traditional development model to science and technology.
中文版
English
